Lantern Pharma Inc. - Common Stock (NQ:LTRN)

0.6354 -0.0053 (-0.83%)

Delayed Quote Updated: 4:00 PM EDT, Oct 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Lantern Pharma Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

BioMedNewsBreaks — Lantern Pharma Inc. (LTRN) Expands HARMONIC™ Trial to Asia with First Patient Dosed in Taiwan

December 18, 2024

Via Investor Brand Network

Topics Artificial Intelligence

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

December 13, 2024

Via Benzinga

Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients

December 09, 2024

From Lantern Pharma Inc.

Via Business Wire

Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)

December 03, 2024

From Lantern Pharma Inc.

Via Business Wire

Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality

November 26, 2024

From Lantern Pharma Inc.

Via Business Wire

Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients

November 19, 2024

From Lantern Pharma Inc.

Via Business Wire

Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates

November 07, 2024

From Lantern Pharma Inc.

Via Business Wire

Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board

November 05, 2024

From Lantern Pharma Inc.

Via Business Wire

Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET

October 31, 2024

From Lantern Pharma Inc.

Via Business Wire

Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024

October 23, 2024

From Lantern Pharma Inc.

Via Business Wire

Lantern Pharma to Host & Participate in Two Public Webinars During October

October 21, 2024

From Lantern Pharma Inc.

Via Business Wire

Lantern Pharma’s Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA

October 15, 2024

From Lantern Pharma Inc.

Via Business Wire

Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children’s Cancers

September 23, 2024

From Lantern Pharma Inc.

Via Business Wire

LTRN Stock Earnings: Lantern Pharma Beats EPS for Q2 2024 ↗

August 08, 2024

LTRN stock results show that Lantern Pharma beat analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

Lantern Pharma Reports Second Quarter 2024 Financial Results and Business Updates

August 08, 2024

From Lantern Pharma Inc.

Via Business Wire

Lantern Pharma Highlights Promising Preclinical Results of LP-184’s Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024

August 07, 2024

From Lantern Pharma

Via Business Wire

Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient Cohort

August 05, 2024

From Lantern Pharma

Via Business Wire

Lantern Pharma to Report Second Quarter 2024 Operating & Financial Results on August 8th, 2024 at 4:30 p.m. ET

August 01, 2024

From Lantern Pharma Inc.

Via Business Wire

Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184

July 10, 2024

From Lantern Pharma

Via Business Wire

Lantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284

June 12, 2024

From Lantern Pharma Inc.

Via Business Wire

12 Health Care Stocks Moving In Monday's After-Market Session ↗

May 13, 2024

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

May 10, 2024

Via Benzinga

LTRN Stock Earnings: Lantern Pharma Misses EPS for Q1 2024 ↗

May 09, 2024

LTRN stock results show that Lantern Pharma missed analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights

May 09, 2024

From Lantern Pharma Inc.

Via Business Wire

Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism

May 06, 2024

From Lantern Pharma Inc.

Via Business Wire

Lantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ET

May 02, 2024

From Lantern Pharma Inc.

Via Business Wire

3 Machine Learning Stocks with the Potential to Make You an Overnight Millionaire ↗

May 01, 2024

Keep an eye on machine learning stocks. With big demand, we could be looking at a half-trillion-dollar market by 2030.

Via InvestorPlace

Lantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development

April 24, 2024

From Lantern Pharma Inc.

Via Business Wire

Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan

April 22, 2024

From Lantern Pharma Inc.

Via Business Wire

Why Wang & Lee Group Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket ↗

April 19, 2024

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.